We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Legend, Janssen Pick Up FDA Approval for Co-Developed CAR-T Treatment
Legend, Janssen Pick Up FDA Approval for Co-Developed CAR-T Treatment
Carvykti, a new CAR-T cell therapy developed by Legend Biotech and Janssen, is now approved for patients with relapsed or refractory multiple myeloma who have already received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.